Arctic Bioscience (ABS) – manufacturing facility and general update November 25 2021 1030 CET

0
Arctic Bioscience (ABS) - manufacturing facility and general update November 25 2021 1030 CET

Arctic Bioscience (ABS) is now starting the construction of a factory for the production of extracts from herring roe for dietary supplements and pharmaceutical products.  In recent days, ABS has received significant attention from news agencies such as TV2 and NRK.

Arctic Bioscience currently sells its products as omega-3 supplements under the product name Romega with sales in Europe, the USA and Asia.

The company has conducted a pilot study for the use of herring roe extracts as a drug for the treatment of moderate psoriasis with excellent results. On the back of this, a larger international phase IIb study will be initiated in Q1 2022. The company is also in the process of developing a drug to help the brain development of extremely premature infants.

Nutra and Pharma share a proprietary technology and IP platform with several patents where, as recently as mid-November, a patent was obtained for a method for using extracts from herring roe in diabetes.

The company’s top management has a background from major international pharmaceutical companies. Now CEO Ole Arne Eiksund, CFO Danielle Glenn and Medical Director Runhild Gammelsæter will come to talk about the factory, current operations and plans for the future. If you want the company to answer questions, you can send them to info@xtrainvestor.com

You may also like

12327

Page 1 of 27

LEAVE A REPLY

Please enter your comment!
Please enter your name here